Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)

Amylyx Pharmaceuticals' EBT Margin history runs 4 years deep, the most recent figure standing at 6003.3% for Q4 2024.

• On a quarterly basis, EBT Margin rose 599921.0% year-over-year to 6003.3% in Q4 2024; TTM through Sep 2025 was 23571.86%, a 2370257.0% increase from a year earlier, with the FY2024 full-year figure at 345.69%, down 35942.0% from the prior year.
• EBT Margin climbed to 6003.3% in Q4 2024 per AMLX's latest filing, from 17476.92% in the prior quarter.
• Across five years, EBT Margin topped out at 6003.3% in Q4 2024 and bottomed at 17476.92% in Q3 2024.
• The 4-year median for EBT Margin is 133.74% (2024), against an average of 3872.44%.
• Across the five-year window, EBT Margin surged 1563950 bps in 2023 and tumbled 1749875 bps in 2024, its largest moves.
• Year by year, EBT Margin stood at 8120.0% in 2021, then jumped by 98 bps to 197.52% in 2022, then surged by 102 bps to 4.1% in 2023, then jumped by 146467 bps to 6003.3% in 2024.
• Per Business Quant, the three latest AMLX EBT Margin figures stand at 6003.3% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024).